Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
d-Amphetamine Transdermal System in Children and Adolescents with ADHD
NCT01711021Phase 2Completed
- Sponsor
- Noven Pharmaceuticals
- Start
- Oct 2012
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dextroamphetamine in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Noven Pharmaceuticals. Primary endpoint: Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Total Score at 12 hours. Started Oct 2012; status: completed.
02
Drugs
dextroamphetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01711021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01711021.